HKU Scholars Hub: Browsing DSpace

Browsing by Author Sherman, M

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 1 to 9 of 9

	Title	Author(s)	Issue Date	Views
	Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir Journal:Hepatology	Leung, N Peng, CY Hann, HW Sollano, J LaoTan, J Hsu, CW Lesmana, L Yuen, MF Jeffers, L Sherman, M Min, A Mencarini, K Diva, U Cross, A Wilber, R LopezTalavera, J	2009	176
	Entecavir (ETV) Results in Higher HBV-DNA Reduction vs Adefovir (ADV) In Chronically Infected HBeAg(+) Antiviral-Naive Adults: 48-Week Results (E.A.R.L.Y. STUDY) Proceeding/Conference:Digestive Disease Week	Leung, N Sherman, M Peng, CY Sollano, JD Lesmana, L Yuen, RMF Jeffers, L Hann, HW Menearini, K Colonno, R Cross, A Wilber, R Lopez-Talavera, JC	2007	100
	Entecavir (ETV) therapy in chronic hepatitis B patients previously treated with adefovir (ADV) with incomplete response on-treatment or relapse off-treatment Proceeding/Conference:Journal of Hepatology	Lai, CL Elion, R Sherman, M Hann, HW Tyrell, DL Hsu, CW Tan, CK Peng, CY Leung, N Mercarni, K Zhang, H Iloeje, UH Kreter, B	2009	178
	Entecavir (ETV) Therapy in Chronic Hepatitis B Patients Previously Treated with Adefovir (ADV) with Incomplete Response On-Treatment or Relapse Off-Treatment Proceeding/Conference:Gastroenterology	Lai, CL Elion, RA Sherman, M Hann, HW Tyrell, DL Hsu, CW Tan, CK Peng, CY Leung, N Mencarini, KA Zhang, H Iloeje, UH Kreter, B	2009	97
	Entecavir (ETV) vs. Adefovir (ADV): HBV DNA reduction of viral load in chronically infected HBeAg(+) nucleoside naive adults in a 12-week Proceeding/Conference:Journal of clinical virology	Sherman, M Hann, HW Jeffers, L Min, A Leung, N Peng, CY Liaw, YF Sollano, J Lesmana, L Yuen, RMF Zhu, J Mencarini, K Colonno, R Cross, A Wilber, R Lopez-Talavera, JC	2006	151
	Entecavir results in higher HBV DNA reduction vs adefovir in chronically infected HBeAg(+) antiviral-naive adults: 24 wk results (EARLY study) Proceeding/Conference:Hepatology	Leung, N Peng, CY Sollano, J Lesmana, L Yuen, RMF Jeffers, L Han, HW Sherman, M Zhu, J Menearini, K Colonno, RJ Cross, A Wilber, R Lopez-Talavera, JC	2006
	Long-term follow-up of entecavir treated protocol-defined non responders in rollover study ETV-901 Proceeding/Conference:Hepatology	Sherman, M Rizzetto, M Lai, CL Liaw, YF Gadano, A Jacobson, IM Schiff, ER Yang, J Colonno, R Kreter, B Hindes, R	2007	69
	Phase 3, randomized, double-blind, dummy-controlled, trial of radiofrequency ablation (RFA) + lyso-thermosensitive liposomal doxorubicin (LTLD, Thermodox), for hepatocellular carcinoma (HCC) lesions 3-7 cm Proceeding/Conference:Annual Conference of the International Liver Cancer Association, ILCA 2013	Tak, WY Lin, SM Wang, Y Zheng, J Izzo, F Park, SY Chen, MH Wong, SN Xu, R Peng, CY Chiou, YY Huang, GT Lee, JY Sherman, M Abdullah, BJJ Lee, JS Wang, JH Borys, N Poon, RTP Lencioni, R	-	83
	Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection Journal:Hepatology	De Man, RA Wolters, LMM Nevens, F Chua, D Sherman, M Lai, CL Gadano, A Lee, Y Mazzotta, F Thomas, N DeHertogh, D	2001

Showing results 1 to 9 of 9